Voydeya Alternatives Compared
Voydeya (danicopan) | Ultomiris (ravulizumab) | Empaveli (pegcetacoplan) |
|
---|
Voydeya (danicopan) | Ultomiris (ravulizumab) | Empaveli (pegcetacoplan) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Paroxysmal Nocturnal Hemoglobinuria. Voydeya may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder, Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria. Ultomiris may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Paroxysmal Nocturnal Hemoglobinuria. Empaveli may also be used for purposes not listed in this medication guide. |
Related suggestions Paroxysmal Nocturnal Hemoglobinuria
|
|||||||||||||||
More about Voydeya (danicopan) | More about Ultomiris (ravulizumab) | More about Empaveli (pegcetacoplan) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Be the first to share your experience with this drug. |
Ultomiris has an average rating of 9.5 out of 10 from a total of 8 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
View all Voydeya side effects |
View all Ultomiris side effects |
View all Empaveli side effects |
||||||||||||||||
Drug Class | ||||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Voydeya prices |
View all Ultomiris prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||||||||||
Dosage Forms | ||||||||||||||||||
|
|
N/A |
||||||||||||||||
Brand Names | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
7.9 hours |
1192.8 hours |
192 hours |
||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 219 drugs are known to interact with Voydeya:
|
A total of 89 drugs are known to interact with Ultomiris:
|
A total of 82 drugs are known to interact with Empaveli:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
March 29, 2024 |
December 21, 2018 |
N/A |
||||||||||||||||
WADA Class View classifications | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient Resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.